Type 2 Diabetes
Conditions
Interventions
Group A:Orally taken nateglinide 120mg
Group B:Orally taken nateglinide 120mg
Group C:Orally taken nateglinide 120mg
Group D:Orally taken nateglinide 120mg
Sponsors
Institute of Clinical Pharmacology, Central South University
Eligibility
Sex/Gender
Male
Age
18 Years to 27 Years
Inclusion criteria
Inclusion criteria: 1. Male, aged between 18 and 27 years; 2. Weight over than 50kg, and BMI between 19 and 25 kg/m2; 3. Healthy on the basis of a medical history, vital signs, physical examination, electrocardiogram (ECG; 4. Provided signed informed consent prior to beginning protocol-specific procedures, indicating that they understood the purpose of this study and were willing to adhere to the treatment regimen and study procedure described in this protocol; 5. No other drugs were taken within 2 week prior to the first dosing.
Exclusion criteria
Exclusion criteria: 1. History of cardiac arrhythmia, bronchospastic or cardiovascular disease, diabetes mellitus, thyrotoxicosis, parkinsonism, or any other disease or physical condition which could have interfered with the interpretation of the study results; 2. Known significant bleeding diathesis which could have precluded multiple venipunctures; 3. Any gastrointestinal condition that could have affected drug absorption or metabolism; 4. History of drug abuse within past 5 years or positive urine drug screen results; 5. Use of concomitant medication within 14 days before the first dose; 6. Participation in an investigational drug trial within 30 days prior to the first visit or intention to take another investigational drug during the course of the study; 7. Significant loss or donation of blood or plasma (500 mL) within 30 days prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of nateglinide;Plasma glucose concentration; | — |
Countries
China
Contacts
Public ContactHong-Hao Zhou
Outcome results
None listed